Revive Prostrate
Revive Prostrate, licence 80122602: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Revive MD supplement Company LLC
- NPN or DIN-HM
- 80122602
- Status
- Active licence
- Licence date
- 6 January 2023
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Urtica dioica L.: L'étiquetage des compléments alimentaires contenant les parties souterraines de cette plante doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Sélénium Source : Citrate de sélénium | 8.33 mcg | Not calculated |
| Zinc Source : Diglycinate de zinc | 1.66 mg | Not calculated |
| Cuivre Source : Diglycinate de cuivre (II) | 83.33 mcg | Not calculated |
| Cucurbita pepo Source : Cucurbita pepo - Graine | 166.66 mg | Not calculated |
| Serenoa repens Extract : Matériel brut sec Extraction ratio : 5:1 Dry plant equivalent : 333.3 mg | 66.66 mg | Not calculated |
| Urtica dioica Extract : Matériel brut sec Extraction ratio : 20:1 Dry plant equivalent : 1000 mg | 50.0 mg | Not calculated |
| 3,3'-Diindolylméthane Source : 3,3'-diindolylméthane | 50.0 mg | Not calculated |
| (3bêta)-Stigmast-5-én-3-ol Source : Helianthus annuus - Graine | 25.0 mg | Not calculated |
| (3bêta)-Stigmast-5-én-3-ol Source : Beta-sitosterol | 25.0 mg | Not calculated |
| Pinus pinaster Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 83.3 mg Potency : 95.0 % Proanthocyanidins | 8.33 mg | Not calculated |
| Lycopène tout trans Source : Lycopène | 3.33 mg | Not calculated |
Non-medicinal ingredients
Phosphate de calcium, dibasique, Stéarate de magnésium, Dioxyde de silicium, Hydroxypropylméthylcellulose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Hommes | minimum: 18.0 ans | 3.0 Capsule | 1.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Source of/Provides antioxidants that help fight/protect (cells) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals. Helps to support prostate health. Stinging Nettle is used in Herbal Medicine to help reduce difficulty in urination associated with the early stages of benign prostatic hyperplasia (BPH). Saw Palmetto is used in Herbal Medicine to help relieve the urologic symptoms (e.g. weak urine flow/incomplete voiding/frequent daytime/night time urination) associated with mild to moderate benign prostatic hyperplasia (BPH).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80122602
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.